Metastatic Low‐Grade Glioma Successfully Treated in a Pediatric Patient With <scp>BRAF</scp> A598_T599insI Mutation
This case highlights the potential of RAF/MEK inhibitors in rare BRAF-mutated tumors and underscores the need for research to optimize treatment duration, manage side effects, and explore their role in non-canonical mutations.
Authors
- Pierluigi Calò (ORCID: https://orcid.org/0000-0002-6867-4031)
- Nathalie Gilis (ORCID: https://orcid.org/0000-0001-5455-3872)
- Marco Preziosi (ORCID: https://orcid.org/0000-0003-1166-442X)
- Laetitia Lebrun (ORCID: https://orcid.org/0000-0002-5663-8180)
- Pierre Leblond (ORCID: https://orcid.org/0000-0002-7088-2614)
- Safiatou Diallo
Institutions
- Université Libre de Bruxelles (BE)
- Erasmus Hospital (BE)
- Institut d’Hématologie et d’Oncologie Pédiatrique (FR)
- Queen Fabiola Children's University Hospital (BE)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1002/cnr2.70309
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63